Skip to main content

Table 2 Multivariate analysis of outcomes based on patient, disease, and transplant characteristics

From: Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia

Variable

Grade II–IV, acute GVHD

Chronic GVHD

Relapse

NRM

LFS

OS

GRFS

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

Donor source

MMUD

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

CBT

1.32 (1–1.74)

0.052

0.94 (0.68–1.3)

0.69

1.35 (1–1.83)

0.05

2.09 (1.46–2.99)

 < 0.0001

1.68 (1.34–2.12)

 < 0.0001

1.7 (1.33–2.17)

 < 0.0001

1.49 (1.21–1.83)

0.0002

Patient age (per 10 years)

1.11 (1.02–1.21)

0.02

1.06 (0.96–1.17)

0.24

0.99 (0.9–1.08)

0.81

1.31 (1.18–1.45)

 < 0.001

1.12 (1.05–1.2)

 < 0.001

1.19 (1.11–1.28)

 < 0.001

1.07 (1.01–1.14)

0.02

Pre-HCT disease status

CR1

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

CR2

1.05 (0.81–1.35)

0.72

1.08 (0.8–1.45)

0.63

1.07 (0.78–1.48)

0.67

1.3 (0.97–1.74)

0.08

1.2 (0.97–1.48)

0.10

1.26 (1.01–1.58)

0.04

1.14 (0.94–1.38)

0.20

Advanced

0.78 (0.57–1.08)

0.13

0.95 (0.61–1.5)

0.84

2.89 (2.19–3.83)

 < 0.001

2.03 (1.47–2.8)

 < 0.001

2.42 (1.96–2.99)

 < 0.001

2.57 (2.07–3.21)

 < 0.001

1.81 (1.48–2.21)

 < 0.001

Cytogenetics

Good risk

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

Intermediate risk

1.22 (0.75–2)

0.42

0.75 (0.45–1.24)

0.26

1.59 (0.77–3.31)

0.21

0.81 (0.48–1.35)

0.41

1.09 (0.72–1.65)

0.69

1.07 (0.69–1.66)

0.75

0.94 (0.66–1.34)

0.73

Adverse risk

1.37 (0.8–2.34)

0.25

0.69 (0.37–1.26)

0.22

3.78 (1.79–7.98)

 < 0.001

0.75 (0.41–1.36)

0.34

1.74 (1.12–2.71)

0.01

1.48 (0.93–2.36)

0.10

1.36 (0.92–1.99)

0.12

Unknown risk

1.32 (0.79–2.19)

0.29

0.88 (0.52–1.5)

0.64

1.92 (0.92–4)

0.08

0.85 (0.5–1.44)

0.54

1.23 (0.81–1.88)

0.33

1.2 (0.77–1.87)

0.42

1.18 (0.82–1.7)

0.36

Donor gender

Male donor

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

Female donor

0.82 (0.67–1.01)

0.06

0.9 (0.7–1.15)

0.40

0.94 (0.74–1.2)

0.62

0.87 (0.69–1.11)

0.26

0.9 (0.76–1.06)

0.22

0.91 (0.76–1.08)

0.29

0.83 (0.71–0.97)

0.02

Conditioning regimen

MAC

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

RIC

0.89 (0.69–1.14)

0.34

0.86 (0.64–1.16)

0.33

1.27 (0.97–1.64)

0.08

0.6 (0.46–0.8)

 < 0.001

0.86 (0.71–1.03)

0.10

0.79 (0.65–0.97)

0.02

0.85 (0.71–1.01)

0.06

KPS ≥ 90

0.74 (0.58–0.94)

0.02

1.19 (0.86–1.64)

0.30

0.95 (0.72–1.24)

0.69

0.8 (0.6–1.05)

0.10

0.87 (0.72–1.05)

0.16

0.86 (0.7–1.05)

0.15

0.85 (0.71–1.02)

0.09

Centre (frailty)

 

 < 0.001

 

 < 0.001

 

0.24

 

0.03

 

0.30

 

0.18

 

0.10

  1. CBT cord blood transplant, MMUD mismatched unrelated donor, CR complete remission, GVHD graft-versus-host disease, NRM non-relapse mortality, PFS progression-free survival, OS overall survival, GRFS GVHD-relapse-free survival, KPS Karnofsky performance scale, RIC reduced intensity conditioning, MAC myeloablative conditioning, HR hazard ratio, CI confidence interval